Global Bioenergies’ H1 results demonstrate good operational execution and strong cash control. The company’s current cash allows for capital spend well in line with our expectations. We note further operational progress with additional process adaptation to second-generation sucrose feedstocks. Our DCF-based valuation range remains €35-63 per share.
24 Sep 2015
On the road to commerciality
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
On the road to commerciality
Global Bioenergies’ H1 results demonstrate good operational execution and strong cash control. The company’s current cash allows for capital spend well in line with our expectations. We note further operational progress with additional process adaptation to second-generation sucrose feedstocks. Our DCF-based valuation range remains €35-63 per share.